Skip to main content

Table 4 Medication use in pediatric IgA vasculitis patients of different onset age

From: Onset age is a risk factor for refractory pediatric IgA vasculitis: a retrospective cohort study

 

Total (n = 484)

≤6 Y (n = 234)

6–12 Y (n = 210)

12–18 Ya (n = 40)

P value

CS

406 (83.9%)

193 (82.5%)

179 (85.2%)

34 (85.0%)

0.718

NSAIDs

436 (90.1%)

216 (92.3%)

188 (89.5%)

32 (80.0%)

0.518

DMARDs

253 (52.3%)

91 (38.9%)

133 (63.3%)

29 (72.5%)

<  0.001

 Azathioprine

224 (46.3%)

83 (35.5%)

119 (56.7%)

22 (55.0%)

<  0.001

 Cyclosporine

64 (13.2%)

20 (8.5%)

33 (15.7%)

11 (27.5%)

0.002

 hydroxychloroquine

61 (12.6%)

22 (9.4%)

29 (13.8%)

10 (25.0%)

0.018

 Othersb

32 (6.6%)

3 (1.3%)

18 (8.6%)

11 (27.5%)

<  0.001

  1. Data shown are number (%) of patients
  2. Abbreviations: IgA Immunoglobulin A, CS Corticosteroid, NSAIDs Non-steroidal anti-inflammatory drugs, DMARDs Disease-modifying anti-rheumatic drugs
  3. a Patients were grouped by onset age: ≤ 6 Y (years old), 6–12 Y (> 6, ≤ 12 years old), and 12–18 Y (> 12, < 18 years old)
  4. b Other DMARDs included mesalazine, sulfasalazine, dapsone, colchicine, methotrexate, and mycophenolate mofetil
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096